Navigation Links
MacuSight Expands Management Team With Appointment of Dr. Joel Naor as Chief Medical Officer
Date:2/20/2008

UNION CITY, Calif., Feb. 20 /PRNewswire/ -- MacuSight(TM), Inc., a developer of innovative therapeutics for the treatment of severe ocular diseases and conditions, today announced the appointment of Joel Naor, M.D., M.Sc., MBA, as the company's chief medical officer. With broad expertise in the clinical development of therapeutics for ocular diseases and conditions, Dr. Naor will play a key role in MacuSight's ongoing advancement of its sirolimus program, as well as the company's overall scientific direction. MacuSight is currently developing its proprietary sirolimus product for the treatment of wet age-related macular degeneration (wet AMD) and diabetic macular edema (DME), as well as various additional ocular diseases and conditions.

Formerly, as a senior medical director at Allergan, Inc., Dr. Naor was a key contributor to the medical and scientific direction of the company's two lead retina programs. In his role as the global project team leader for Allergan's POSURDEX(R) program, Dr. Naor oversaw a multifunctional team with responsibilities that spanned clinical development, regulatory, CMC and marketing. Most recently, he served on Allergan's global medical affairs group as a medical director, retina. Prior to his work with Allergen, Dr. Naor was a director of clinical research at QLT, Inc. where he served as a clinical lead on the global project team for Visudyne(R) (verteporfin for injection).

"Through his work at both Allergan and QLT, Joel has gained valuable experience and strategic insight related to the successful advancement of novel ocular therapeutics through clinical trials," stated David A. Weber, Ph.D., president and chief executive officer of MacuSight. "It is this expertise that makes him an ideal fit for MacuSight as we work to aggressively and successfully advance our sirolimus program through clinical development and toward the market. We are excited to have Joel as part of the team and look forward to the key contributions he will make to MacuSight and our clinical programs."

Dr. Naor earned his M.D. from the Technion -- Israel Institute of Technology and underwent cornea and external disease training at the University of Toronto where he also obtained his M.Sc. in epidemiology. He holds a Masters of Business Administration from Simon Fraser University in Vancouver.

"I am thrilled to be joining a management team that has an impressive track record in identifying and advancing novel therapeutics in the area of ophthalmology and which is supported by a scientific advisory board of world-renowned experts," said Dr. Naor. "Clearly, we all believe in the great promise that sirolimus holds in treating various ocular diseases and conditions and I am confident in the ability of MacuSight to realize this potential and deliver a much needed therapeutic option to patients."

About MacuSight

MacuSight is a privately-held pharmaceutical company focused on developing innovative therapeutics for the treatment of severe ocular diseases and conditions. The company is dedicated to preserving patients' vision by identifying known, highly-potent and broad-acting small molecule drug compounds that may possess efficacy in treating and/or preventing diseases or conditions of the eye. As part of its unique product development philosophy, MacuSight also concentrates on the optimal delivery of these compounds into the eye. By combining its compounds with innovative delivery approaches, the company strives to optimize the efficacy, safety, convenience and cost-effectiveness of its product candidates.

The company's lead development program is centered on advancing sirolimus (rapamycin) as a potential next-generation therapeutic for the treatment and prevention of wet age-related macular degeneration (wet AMD) and the treatment of diabetic macular edema (DME), a manifestation of diabetic retinopathy.


'/>"/>
SOURCE MacuSight, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. Veteran Bariatric Surgeon Expands Services to Solano County
2. Tahitian Noni International Expands HIRO(TM) Beverage Line With Super Fruits Sparkling Black Currant
3. Convera(R) Expands Advanstar OnLine Business to Vertical Search Covering Pharmaceutical Industry Applications
4. Hondros College Expands School of Nursing to Columbus and Dayton; Students Can Begin LPN Education Almost Immediately
5. Beryl Expands Leadership Team, Adds Senior VP of Product Management and Marketing
6. Anthem Blue Cross and Blue Shield Expands Network of Hospitals to Serve Hoosier Healthwise Members
7. Henry Ford Hospital expands research on gene and radiation therapy for prostate cancer
8. HearAtLast Expands Chain to 18 Locations Opening New Clinic in Aurora, Ontario Wal-Mart Store # 5778
9. HearAtLast Expands Chain to 17 Locations, Opening New Clinic in Oshawa, Ontario Wal-Mart Supercenter # 1056
10. Cell Therapeutics, Inc. (CTI) Cuts Net Operating Expenses 35% and Expands Commercial Team to Support Zevalin(R) Sales and Applications Seeking Two Product Approvals in 2009
11. SAFC Pharma Expands Its Pharmorphix Solid State Chemistry Services
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/5/2016)... ... May 05, 2016 , ... An essential tool for researching ... certain Canadian provinces is now available from the International Association of Industrial Accident ... The report, Workers’ Compensation Laws as of January 1, 2016, is ...
(Date:5/5/2016)... (PRWEB) , ... May 05, 2016 , ... A recent ... continue to face challenges in getting employees to understand and use the free preventive ... of the nation’s leading non-profit business groups of large, self-insured public and private employers, ...
(Date:5/5/2016)... , ... May 05, 2016 , ... Vitenas Cosmetic Surgery ... Design Awards, presented by the American Institute of Architects and the Academy of Architecture ... the renowned Perkins+Will and Harrell Architects, opened to patients in October of 2014. ...
(Date:5/5/2016)... , ... May 05, 2016 , ... TIME for Kids ... – today announced a new partnership to reach nearly 1 million children with important ... an instant and is the leading cause of accidental death in children one to ...
(Date:5/5/2016)... ... 2016 , ... In order to increase comfort, convenience and ... Seattle-based steam bath and sauna manufacturer recently launched amerecConnect™ , a new ... app, developed for both smartphones and personal computers perfectly emulates that of the ...
Breaking Medicine News(10 mins):
(Date:5/3/2016)... -- Research and Markets has announced the ... Market Outlook 2020" report to their offering. ... technology has improved significantly in past years due to ... coming years. Many cancer drugs have been developed by ... also expected to be developed with its help. They ...
(Date:5/3/2016)... 3, 2016   BIOTRONIK , a leader ... Food and Drug Administration (FDA) approval of Iperia ... heart failure patients with access to diagnostic magnetic ... remote monitoring with daily automatic transmission and closed ... in response to physiological demands. ...
(Date:5/3/2016)... -- Pharmaceutical giant Johnson & Johnson has ... who says its talc-based powder products caused ovarian cancer. ... $5 million in compensatory damages and $50 million in ... ) , This is the second in ... the same court awarded $72 million to the family ...
Breaking Medicine Technology: